
|Videos|July 7, 2016
The Benefits of ASCO's TAPUR Trial
Author(s)Edward S. Kim, MD
Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the prospective benefits of the TAPUR clinical trial, which is being conducted by ASCO.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Switching From Chemoimmunotherapy When a ROS1 Result Returns
2
Building an Adequate ROS1 Workup With RNA-Based Sequencing
3
Etentamig Improves Response, Survival in Phase 3 Trial for Relapsed/Refractory Myeloma
4
CAR T-Cell Therapy Delivers Durable QOL Gains at 2 Years
5


































